中文
  • About Us
    Corporate Overview Management Team Board of Directors Contact Us
  • Our Focus
    Viral Diseases NASH/PBC Cancer Exploratory Indications
  • Products&Pipeline
    Pipeline Products Clinical Trials
  • Partnership
  • Investors
    Financials & Filing Presentation Materials
  • News
  • Careers
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • Ascletis’ IND Filing for Its Third HCV Drug ASC21 Accepted by NMPA

    2019-01-03

  • Ascletis’ Ganovo Enrolled in the Basic Medical Insurance of Chengdu

    2019-01-02

  • «
  •  
  • 1
  • 2
  • 3
  •  
    • © 2018 Ascletis Pharma Inc.
    • 浙公网安备 33010802003344号
    • All Rights Reserved
    • 浙ICP备 11050387号-1

    contact

    • pr@ascletis.com
    • bd@ascletis.com
    • hr@ascletis.com
    • clinicaltrials@ascletis.com

    © 2018 Ascletis Pharma Inc. All Rights Reserved
    浙公网安备 33010802003344号 浙ICP备11050387号-1